Roles and Regulation of BCL-xL in Hematological Malignancies

• Published in: International journal of molecular sciences Vol. 23; no. 4; p. 2193
• Main Authors: Morales-Martínez, Mario, Vega, Mario I
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 16.02.2022; MDPI
• Subjects: Apoptosis; Apoptosis - genetics; B-cell lymphoma; Bcl-2 protein; Bcl-x protein; bcl-X Protein - genetics; bcl-X Protein - metabolism; BCL-xL; Cancer therapies; Cell cycle; Cell Survival; Chemotherapy; Cytokines; Disease; Gene regulation; Hematologic Neoplasms - genetics; hematological malignances; Hematology; Humans; Leukemia; Lymphocytes; Lymphocytes B; Lymphoma; Melanoma; Metastasis; Multiple myeloma; non-Hodgkin’s lymphoma; Proteins; Proto-Oncogene Proteins c-bcl-2 - genetics; Review; Survival; Transcription; BCL-xL; non-Hodgkin’s lymphoma; hematological malignances
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23042193

Members of the Bcl-2 family are proteins that play an essential role in the regulation of apoptosis, a crucial process in development and normal physiology in multicellular organisms. The essential mechanism of this family of proteins is given by the role of pro-survival proteins, which inhibit apoptosis by their direct binding with their counterpart, the effector proteins of apoptosis. This family of proteins was named after the typical member Bcl-2, which was named for its discovery and abnormal expression in B-cell lymphomas. Subsequently, the structure of one of its members BCL-xL was described, which allowed one to understand much of the molecular mechanism of this family. Due to its role of BCL-xL in the regulation of cell survival and proliferation, it has been of great interest in its study. Due to this, it is important to research its role regarding the development and progression of human malignancies, especially in hematologic malignancies. Due to its variation in expression in cancer, it has been suggested that BCL-xL can or cannot play a role in cancer depending on the cellular or tissue context. This review discusses recent advances in its transcriptional regulation of BCL-xL, as well as the advances regarding the activities of BCL-xL in hematological malignancies, its possible role as a biomarker, and its possible clinical relevance in these malignancies.